Literature DB >> 29263214

Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment.

Zilin Nie1, Fatma Aboulnasr1, Sekar Natesampillai1, Stephen P Burke1, Ashton Krogman1,2, Gary D Bren1, Thomas D Y Chung3, Jeff R Anderson3, Michele K Smart1, David J Katzmann4, Govindarajan Rajagopalan2, Nathan W Cummins1, Andrew D Badley5,3,6.   

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) was initially described to induce apoptosis of tumor cells and/or virally infected cells, although sparing normal cells, and has been implicated in the pathogenesis of HIV disease. We previously identified TRAILshort, a TRAIL splice variant, in HIV-infected patients and characterized it as being a dominant negative ligand to subvert TRAIL-mediated killing. Herein, using single-cell genomics we demonstrate that TRAILshort is produced by HIV-infected cells, as well as by uninfected bystander cells, and that the dominant stimulus which induces TRAILshort production are type I IFNs and TLR7, TLR8, and TLR9 agonists. TRAILshort has a short t1/2 by virtue of containing a PEST domain, which targets the protein toward the ubiquitin proteasome pathway for degradation. Further we show that TRAILshort binds preferentially to TRAIL receptors 1 and 2 with significantly reduced interaction with the decoy TRAIL receptors 3 and 4. Recombinant TRAILshort is sufficient to protect cells against TRAIL-induced killing, whereas immunodepletion of TRAILshort with a specific Ab restores TRAIL sensitivity. Importantly we show that TRAILshort is shed in microvesicles into the cellular microenvironment and therefore confers TRAIL resistance not only on the cell which produces it, but also upon neighboring bystander cells. These results establish a novel paradigm for understanding and overcoming TRAIL resistance, in particular how HIV-infected cells escape immune elimination by the TRAIL:TRAILshort receptor axis.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29263214      PMCID: PMC5808399          DOI: 10.4049/jimmunol.1701113

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor.

Authors:  A Truneh; S Sharma; C Silverman; S Khandekar; M P Reddy; K C Deen; M M McLaughlin; S M Srinivasula; G P Livi; L A Marshall; E S Alnemri; W V Williams; M L Doyle
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

2.  Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.

Authors:  J Mongkolsapaya; J M Grimes; N Chen; X N Xu; D I Stuart; E Y Jones; G R Screaton
Journal:  Nat Struct Biol       Date:  1999-11

3.  Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.

Authors:  Almer M van der Sloot; Vicente Tur; Eva Szegezdi; Margaret M Mullally; Robbert H Cool; Afshin Samali; Luis Serrano; Wim J Quax
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-26       Impact factor: 11.205

4.  Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.

Authors:  Gilad Doitsh; Nicole L K Galloway; Xin Geng; Zhiyuan Yang; Kathryn M Monroe; Orlando Zepeda; Peter W Hunt; Hiroyu Hatano; Stefanie Sowinski; Isa Muñoz-Arias; Warner C Greene
Journal:  Nature       Date:  2014-01-23       Impact factor: 49.962

5.  Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis.

Authors:  Julien van Grevenynghe; Rafael A Cubas; Alessandra Noto; Sandrina DaFonseca; Zhong He; Yoav Peretz; Abdelali Filali-Mouhim; Franck P Dupuy; Francesco A Procopio; Nicolas Chomont; Robert S Balderas; Elias A Said; Mohamed-Rachid Boulassel; Cecile L Tremblay; Jean-Pierre Routy; Rafick-Pierre Sékaly; Elias K Haddad
Journal:  J Clin Invest       Date:  2011-09-19       Impact factor: 14.808

6.  Isolation of a TRAIL antagonist from the serum of HIV-infected patients.

Authors:  David J Schnepple; Brett Shepard; Gary D Bren; Nathan W Cummins; Sekar Natesampillai; Sergey Trushin; Alicia Algeciras-Schimnich; Xue W Meng; Amy M Sainski; Stacey A Rizza; Scott H Kaufmann; Andrew D Badley
Journal:  J Biol Chem       Date:  2011-08-22       Impact factor: 5.157

Review 7.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

8.  Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1.

Authors:  Marie-Thérèse Melki; Héla Saïdi; Alexandre Dufour; Jean-Christophe Olivo-Marin; Marie-Lise Gougeon
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

Review 9.  Multifactorial nature of human immunodeficiency virus disease: implications for therapy.

Authors:  A S Fauci
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

10.  BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes.

Authors:  J J Oudejans; A J van den Brule; N M Jiwa; P C de Bruin; G J Ossenkoppele; P van der Valk; J M Walboomers; C J Meijer
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

View more
  6 in total

1.  Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL.

Authors:  Runze Zhao; Yuju Li; Santhi Gorantla; Larisa Y Poluektova; Hai Lin; Fengtong Gao; Hongyun Wang; Jeffrey Zhao; Jialin C Zheng; Yunlong Huang
Journal:  Antiviral Res       Date:  2019-05-31       Impact factor: 5.970

2.  Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells.

Authors:  Fatma Aboulnasr; Ashton Krogman; Rondell P Graham; Nathan W Cummins; Anisha Misra; Enrique Garcia-Rivera; Jeff R Anderson; Sekar Natesampillai; Nicole Kogan; Murali Aravamudan; Zilin Nie; Thomas D Y Chung; Richard Buick; Andrew L Feldman; Rebecca L King; Anne J Novak; Stephen M Ansell; Saad Kenderian; Andrew D Badley
Journal:  Clin Cancer Res       Date:  2020-07-15       Impact factor: 12.531

3.  TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.

Authors:  Sekar Natesampillai; Ana C Paim; Nathan W Cummins; Aswath P Chandrasekar; Gary D Bren; Sharon R Lewin; Hans-Peter Kiem; Andrew D Badley
Journal:  J Immunol       Date:  2019-06-12       Impact factor: 5.422

4.  HIV elite control is associated with reduced TRAILshort expression.

Authors:  Ana C Paim; Nathan W Cummins; Sekar Natesampillai; Enrique Garcia-Rivera; Nicole Kogan; Ujjwal Neogi; Anders Sönnerborg; Maike Sperk; Gary D Bren; Steve Deeks; Eric Polley; Andrew D Badley
Journal:  AIDS       Date:  2019-09-01       Impact factor: 4.177

5.  Analyses of long non-coding RNA and mRNA profiling in the spleen of diarrheic piglets caused by Clostridium perfringens type C.

Authors:  Zunqiang Yan; Xiaoyu Huang; Wenyang Sun; Qiaoli Yang; Hairen Shi; Tiantuan Jiang; Shenggui Li; Pengfei Wang; Shuangbao Gun
Journal:  PeerJ       Date:  2018-11-30       Impact factor: 2.984

6.  The long road to TRAIL therapy: a TRAILshort detour.

Authors:  Aswath P Chandrasekar; Mark Maynes; Andrew D Badley
Journal:  Oncotarget       Date:  2021-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.